JP2007524651A - 多剤耐性遺伝子の発現を抑制して、該遺伝子の発現によって生じるタンパク質の製造を抑制し、それにより、癌治療のための化学療法薬の有効性を高める方法。 - Google Patents
多剤耐性遺伝子の発現を抑制して、該遺伝子の発現によって生じるタンパク質の製造を抑制し、それにより、癌治療のための化学療法薬の有効性を高める方法。 Download PDFInfo
- Publication number
- JP2007524651A JP2007524651A JP2006527239A JP2006527239A JP2007524651A JP 2007524651 A JP2007524651 A JP 2007524651A JP 2006527239 A JP2006527239 A JP 2006527239A JP 2006527239 A JP2006527239 A JP 2006527239A JP 2007524651 A JP2007524651 A JP 2007524651A
- Authority
- JP
- Japan
- Prior art keywords
- group
- azetidinone
- cholesterol absorption
- absorption inhibitor
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 COP(O*)(OC(C(C(CO)O)OC1=O)=C1O*)=O Chemical compound COP(O*)(OC(C(C(CO)O)OC1=O)=C1O*)=O 0.000 description 2
- MCBLWBYKPHUPQS-UHFFFAOYSA-N COP(O)(OC(C(C(CO)O)OC1=O)=C1O)=O Chemical compound COP(O)(OC(C(C(CO)O)OC1=O)=C1O)=O MCBLWBYKPHUPQS-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67305103A | 2003-09-26 | 2003-09-26 | |
PCT/CA2004/001697 WO2005030225A2 (fr) | 2003-09-26 | 2004-09-27 | Methode destinee a inhiber l'expression de genes de multiresistance aux medicaments et a inhiber la production de proteines resultant de l'expression de ces genes en vue d'ameliorer l'efficacite d'agents chimiotherapeutiques pour le traitement des cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2007524651A true JP2007524651A (ja) | 2007-08-30 |
Family
ID=34393484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006527239A Pending JP2007524651A (ja) | 2003-09-26 | 2004-09-27 | 多剤耐性遺伝子の発現を抑制して、該遺伝子の発現によって生じるタンパク質の製造を抑制し、それにより、癌治療のための化学療法薬の有効性を高める方法。 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1677803A2 (fr) |
JP (1) | JP2007524651A (fr) |
KR (1) | KR20060135615A (fr) |
CN (1) | CN1874780A (fr) |
AU (1) | AU2004275444A1 (fr) |
BR (1) | BRPI0414812A (fr) |
CA (1) | CA2540364A1 (fr) |
RU (1) | RU2006114049A (fr) |
WO (1) | WO2005030225A2 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007001975A1 (fr) | 2005-06-20 | 2007-01-04 | Schering Corporation | Dérivés de la pipéridine utiles comme antagonistes du récepteur h3 de l'histamine |
CN102027135B (zh) * | 2008-03-14 | 2015-04-22 | 健泰科生物技术公司 | 与药物抗性有关的遗传变异 |
CN102552284A (zh) * | 2011-12-13 | 2012-07-11 | 陕西师范大学 | 麦角甾醇在制备肿瘤多药耐药逆转药物中的应用 |
MX2016010998A (es) | 2014-02-27 | 2017-03-31 | Lycera Corp | Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados. |
CA2947290A1 (fr) | 2014-05-05 | 2015-11-12 | Lycera Corporation | Sulfonamide de tetrahydroquinoline et composes apparentes destines a servir d'agonistes de rory et pour le traitement de maladies |
JP2018515491A (ja) | 2015-05-05 | 2018-06-14 | リセラ・コーポレイションLycera Corporation | RORγの作動薬及び疾患の療法として使用するジヒドロ−2H−ベンゾ[b][1,4]オキサジンスルホンアミド及び関連化合物 |
KR20180025894A (ko) | 2015-06-11 | 2018-03-09 | 라이세라 코퍼레이션 | Rory의 작용제로서 사용하기 위한 아릴 디히드로-2h-벤조[b][1,4]옥사진 술폰아미드 및 관련 화합물 및 질환의 치료 |
CN106420768B (zh) * | 2015-08-13 | 2018-12-28 | 广州中医药大学第二附属医院 | 赪酮甾醇作为p-糖蛋白抑制剂的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1439595A (en) * | 1993-12-22 | 1995-07-10 | Salk Institute For Biological Studies, The | Methods for reducing multidrug resistance |
ATE381542T1 (de) * | 2001-08-13 | 2008-01-15 | Phenex Pharmaceuticals Ag | Nr1h4-kern-rezeptor-bindende verbindungen |
WO2004010948A2 (fr) * | 2002-07-30 | 2004-02-05 | Karykion Inc. | Compositions d'ezetimibe, et procedes pour le traitement de tumeurs benignes et malignes associees au cholesterol |
-
2004
- 2004-09-27 BR BRPI0414812-6A patent/BRPI0414812A/pt not_active Application Discontinuation
- 2004-09-27 EP EP04761853A patent/EP1677803A2/fr not_active Withdrawn
- 2004-09-27 AU AU2004275444A patent/AU2004275444A1/en not_active Abandoned
- 2004-09-27 KR KR1020067005929A patent/KR20060135615A/ko not_active Application Discontinuation
- 2004-09-27 CA CA002540364A patent/CA2540364A1/fr not_active Abandoned
- 2004-09-27 CN CNA2004800316973A patent/CN1874780A/zh active Pending
- 2004-09-27 RU RU2006114049/15A patent/RU2006114049A/ru unknown
- 2004-09-27 WO PCT/CA2004/001697 patent/WO2005030225A2/fr not_active Application Discontinuation
- 2004-09-27 JP JP2006527239A patent/JP2007524651A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2540364A1 (fr) | 2005-04-07 |
WO2005030225A3 (fr) | 2005-05-26 |
EP1677803A2 (fr) | 2006-07-12 |
AU2004275444A1 (en) | 2005-04-07 |
CN1874780A (zh) | 2006-12-06 |
BRPI0414812A (pt) | 2006-11-14 |
WO2005030225A2 (fr) | 2005-04-07 |
KR20060135615A (ko) | 2006-12-29 |
RU2006114049A (ru) | 2007-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005042692A2 (fr) | Methode permettant d'inhiber l'expression de genes qui induisent l'influx de cholesterol cellulaire dans les cellules animales et d'inhiber la production de proteines issues de l'expression de ces genes | |
US11319337B2 (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
US7098198B2 (en) | Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors | |
JP2010059175A (ja) | 6−フルオロウルソデオキシコール酸(6−fudca)を含む結腸腺腫または結腸微小腺腫の処置または進行の遅延用医薬組成物 | |
EA005815B1 (ru) | Комбинация ингибиторов транспорта желчных кислот в подвздошной кишке и ингибиторов белка, переносящего эфиры холестерина, для сердечно-сосудистых показаний | |
JP2017535608A (ja) | 癌標的化薬物ビヒクルとしてのリン脂質エーテル類似体 | |
JP3041232B2 (ja) | 癌転移抑制剤 | |
JP2007524651A (ja) | 多剤耐性遺伝子の発現を抑制して、該遺伝子の発現によって生じるタンパク質の製造を抑制し、それにより、癌治療のための化学療法薬の有効性を高める方法。 | |
TW201609094A (zh) | 治療癌症之新穎方法 | |
JP2022500453A (ja) | 線維症、nash、及び、nafldを治療する方法での使用のためのトリプトリド、及び、そのプロドラッグ | |
US7432306B2 (en) | Method for preparing novel transcription factors and use | |
NO328733B1 (no) | Fosfolipidkomplekser av proantocyanidin A2, farmasoytisk sammensetning inneholdende kompleksene og anvendelse derav | |
WO2014048313A1 (fr) | Produit de condensation de dérivé théanine et de dérivé coumarine d'acide carboxylique, intermédiaire du produit de condensation, leur procédé de préparation, et leur utilisation | |
US20220024872A1 (en) | Isolation and characterization of anticancer compound from sesuvium portulacastrum (l.) l. | |
JP2005225851A (ja) | 新規転写因子の製造法及び用途 | |
EP3403661B1 (fr) | Extrait dérivé d'un organisme marin, composé, et composition à visée médicale ayant une activité de suppression de formation de niches dans les cellules souches leucémiques | |
KR20210108165A (ko) | Ksp 억제제와 유사분열 억제제를 포함하는 암의 예방 또는 치료용 약학 조성물 | |
CA2518328C (fr) | Methode de preparation de nouveaux facteurs de transcription et utilisation connexe | |
TW202019391A (zh) | 含有7β-羥膽固醇及脂質載體之組合物及其用於治療腫瘤性病理學之用途 |